AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14517707 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 100 mg
Number of subjects: 18
Study 14517707 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 200 mg
Number of subjects: 18
Study 14517707 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 400 mg
Number of subjects: 18
Study 14517707 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 3-202 (all doses)
Number of subjects: 18
Study 14517707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11081780 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute salt loading with a 2 h infusion of isotonic saline
Number of subjects: 24
Study 11081780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-, regular-, and high-sodium diet for 1 week
Number of subjects: 24
Study 11081780 — intervention group
Group type: COMPARATOR
Intervention: Acute water loading
Number of subjects: 24
Study 8817257 — intervention group
Group type: EXPERIMENTAL
Intervention: Small stimulus followed 50 ms later by large stimulus (masked stimulus)
Number of subjects: 0
Study 8817257 — intervention group
Group type: COMPARATOR
Intervention: Same stimulus presented without masking (easily perceived)
Number of subjects: 0
Study 1575145 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled catheter
Number of subjects: 125
Study 3936056 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (20 mg, 3-times daily)
Number of subjects: 50
Study 3936056 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release glyceryl trinitrate (6.4 mg, 3-times daily)
Number of subjects: 50
Study 30811594 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple CARE program (CCP) for parents of newborns; uncontrolled demonstration project (Study 1)
Number of subjects: 0
Study 30811594 — intervention group
Group type: COMPARATOR
Intervention: Couple CARE program (CCP) for parents of newborns; randomized controlled trial (Study 2)
Number of subjects: 0
Study 30811594 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple CARE program (CCP) for parents of newborns; evaluated with low-income parents from urban hospitals (Study 3 and Study 4)
Number of subjects: 0
Study 30463925 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoFMT (autologous fecal microbiota transplantation)
Number of subjects: 10
Study 30463925 — intervention group
Group type: COMPARATOR
Intervention: Saline enema (control)
Number of subjects: 10
Study 30463925 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate (Amox-Clav)
Number of subjects: 10
Study 26656205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (caloric intake increase)
Number of subjects: 0
Study 26656205 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactuals from the model
Number of subjects: 0
Study 24637411 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1800 mg/day) + statin (rosuvastatin)
Number of subjects: 30
Study 24637411 — intervention group
Group type: COMPARATOR
Intervention: Statin (rosuvastatin) only
Number of subjects: 30
Study 22465423 — intervention group
Group type: EXPERIMENTAL
Intervention: Community empowerment strategy with four components: organisation and management, entomological risk surveillance, capacity building, and community work for vector control.
Number of subjects: 32
Study 22465423 — intervention group
Group type: EXPERIMENTAL
Intervention: Community empowerment strategy
Number of subjects: 32
Study 22465423 — intervention group
Group type: COMPARATOR
Intervention: Routine activities without interference (Control)
Number of subjects: 32
Study 19268930 — intervention group
Group type: EXPERIMENTAL
Intervention: SureView catheter
Number of subjects: 175
Study 19268930 — intervention group
Group type: COMPARATOR
Intervention: Wallace catheter
Number of subjects: 175
Study 17493557 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeled glenoid components
Number of subjects: 20
Study 17493557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegged glenoid components
Number of subjects: 20
Study 15982282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 40
Study 15982282 — intervention group
Group type: COMPARATOR
Intervention: Non-cardiopulmonary bypass (non-CPB)
Number of subjects: 40
Study 11945144 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2b interferon (IFN‐R)
Number of subjects: 168
Study 11945144 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte alpha n‐3 interferon (IFN‐L)
Number of subjects: 168
Study 9718470 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg orally once daily for 3 days)
Number of subjects: 174
Study 9718470 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (7.5 mg/kg orally twice daily for 10 days)
Number of subjects: 174
Study 7581311 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury-prevention education programs including Window Guards campaign, Safety City Program, KISS, Burn Prevention Curriculum, Smoke Detector Distribution, Harlem Alternative to Violence Program, Adolescent Outreach Program, Critical Incident Stress Management Teams.
Number of subjects: 0
Study 7581311 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs providing safe activities and environments including Bicycle Safety Program/Urban Youth Bike Corps, Playground Injury Prevention Program, Greening of Harlem Program, Harlem Horizon Art Studio, Harlem Hospital Dance Clinic, Unity through Murals project, baseball at Harlem Little League, winter baseball clinic, soccer league.
Number of subjects: 0
Study 2526959 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 0.02 mg
Number of subjects: 15
Study 2526959 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 0.2 mg (control)
Number of subjects: 15
Study 332505 — intervention group
Group type: EXPERIMENTAL
Intervention: practolol 100 mg
Number of subjects: 6
Study 332505 — intervention group
Group type: EXPERIMENTAL
Intervention: practolol 400 mg
Number of subjects: 6
Study 332505 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 31070702 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 796
Study 31070702 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEis)
Number of subjects: 796
Study 31694631 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected dexamethasone
Number of subjects: 13
Study 28320603 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction recommendations on diet and physical activities (Group B)
Number of subjects: 95
Study 28320603 — intervention group
Group type: COMPARATOR
Intervention: No specific counseling on diet or activity (Group A)
Number of subjects: 95
Study 26416084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive leadership training
Number of subjects: 110
Study 26416084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supportive leadership training)
Number of subjects: 110
Study 23743855 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention with provision of HF educational information
Number of subjects: 902
Study 23743855 — intervention group
Group type: COMPARATOR
Intervention: Enhanced education control group receiving the same HF educational materials
Number of subjects: 902
Study 22267465 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (900/100 mg once daily)
Number of subjects: 19
Study 22267465 — intervention group
Group type: EXPERIMENTAL
Intervention: raltegravir (400 mg twice daily)
Number of subjects: 19
Study 19175441 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent practice-change intervention
Number of subjects: 644
Study 17224706 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-15 mg once daily, starting dose = 9 mg)
Number of subjects: 205
Study 17224706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 17224706 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 205
Study 15231013 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (combined doses of 60 mg/day and 120 mg/day)
Number of subjects: 7705
Study 15231013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 15231013 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705
Study 15231013 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study 11281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols and their derivatives
Number of subjects: 0
Study 11281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Various mixtures of plant sterols
Number of subjects: 0
Study 11281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol consumption
Number of subjects: 0
Study 9733025 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail: 90 mg of Q10 and 13.5 mg of d‐alpha‐tocopheryl acetate daily (18 men)
Number of subjects: 37
Study 9733025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (19 men)
Number of subjects: 37
Study 9733025 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Number of subjects: 37
Study 8289481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) 2 x 10 mg/m2 subcutaneously (s.c.) days 1‐14 plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) 2 x 150 micrograms protein/day s.c. given either following Ara C (days 15‐21) or simultaneously (days 8‐14) for 1‐5 cycles.
Number of subjects: 108
Study 8289481 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside (LD-AraC) alone (not explicitly mentioned but referenced as ongoing evaluation).
Number of subjects: 108
Study 3188048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3
Number of subjects: 24
Study 3188048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 ppm NO2
Number of subjects: 24
Study 3188048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined O3 and NO2 exposure
Number of subjects: 24
Study 3188048 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 24
Study 1565294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplements (800 mg dl‐alpha‐tocopherol acetate) for 30 days
Number of subjects: 0
Study 1565294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 755040 — intervention group
Group type: EXPERIMENTAL
Intervention: methysergide (serotonin receptor blocker)
Number of subjects: 10
Study 755040 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 755040 — intervention group
Group type: EXPERIMENTAL
Intervention: methysergide
Number of subjects: 10
Study 30247332 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal resection (Lap)
Number of subjects: 475
Study 30247332 — intervention group
Group type: COMPARATOR
Intervention: Open laparotomy and rectal resection (Open)
Number of subjects: 475
Study 28086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nutrition education programme promoting vegetable intake (350 g per day, five small bowls)
Number of subjects: 1500
Study 28086921 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nutrition education programme
Number of subjects: 1500
Study 25404086 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (SRL) - removed CNI and increased sirolimus
Number of subjects: 45
Study 25404086 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus (TAC) - maintained CNI
Number of subjects: 45
Study 24954343 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and music intervention for 30 min before surgery
Number of subjects: 40
Study 24954343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 23059780 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 255
Study 23059780 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib-bexarotene
Number of subjects: 255
Study 23059780 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 255
Study 23059780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 255
Study 23059780 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 255
Study 19438416 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once-daily
Number of subjects: 87
Study 19438416 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice-daily
Number of subjects: 87
Study 19438416 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once-daily
Number of subjects: 87
Study 19438416 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice-daily
Number of subjects: 87
Study 19438416 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (once-daily) vs Lansoprazole (once-daily)
Number of subjects: 87
Study 19438416 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (twice-daily) vs Lansoprazole (twice-daily)
Number of subjects: 87
Study 17307447 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of indicated secondary prevention medications (antiplatelet agents, beta-blockers, ACE inhibitors or ARBs, lipid-lowering agents)
Number of subjects: 2970
Study 17307447 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of indicated secondary prevention medications
Number of subjects: 2970
Study 15362759 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative music therapy with a key-lighting keyboard system (Group A)
Number of subjects: 50
Study 15362759 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 50
Study 11274935 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 128
Study 11274935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 9844956 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 54
Study 9844956 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX-CRH test
Number of subjects: 54
Study 9844956 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric measurements
Number of subjects: 54
Study 9844956 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual assessment
Number of subjects: 54
Study 7983994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral homoeopathic immunotherapy to their principal allergen
Number of subjects: 28
Study 7983994 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 28
Study 2689183 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (2 mg)
Number of subjects: 10
Study 2689183 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (20 mg)
Number of subjects: 10
Study 30057055 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week Hatha yoga exercise program
Number of subjects: 42
Study 30057055 — intervention group
Group type: COMPARATOR
Intervention: 10-week follow-up program (Control)
Number of subjects: 42
Study 27092784 — intervention group
Group type: COMPARATOR
Intervention: Hickman catheter
Number of subjects: 100
Study 27092784 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVAS
Number of subjects: 100
Study 24149925 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of soy flour (whole soy group)
Number of subjects: 270
Study 24149925 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of low-fat milk powder + 63 mg of daidzein (daidzein group)
Number of subjects: 270
Study 24149925 — intervention group
Group type: COMPARATOR
Intervention: 40 g of low-fat milk powder (placebo group)
Number of subjects: 270
Study 22990513 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (20/30 made-to-measure) worn during 30 minutes of walking on a treadmill
Number of subjects: 16
Study 22990513 — intervention group
Group type: COMPARATOR
Intervention: No compression stockings (control group)
Number of subjects: 16
Study 20132927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes
Number of subjects: 104
Study 20132927 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 104
Study 20132927 — intervention group
Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 104
Study 20132927 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (both nicotine and denicotinized)
Number of subjects: 104
Study 20132927 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reinforcement
Number of subjects: 104
Study 18594318 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex (PPX) 175 mg/m
Number of subjects: 0
Study 18594318 — intervention group
Group type: COMPARATOR
Intervention: Control (single-agent vinorelbine or gemcitabine)
Number of subjects: 0
Study 18594318 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex (PPX)
Number of subjects: 0
Study 16403289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic propyl gallate (C‐PG) at 100‐300 micromol/L
Number of subjects: 516
Study 16403289 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) at 200‐400 mg
Number of subjects: 516
Study 16403289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic propyl gallate (C‐PG) as inducer of platelet aggregation
Number of subjects: 516
Study 16403289 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated plasma clotting time (APCT) examination
Number of subjects: 516
Study 12186195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization advice by primary care providers
Number of subjects: 162
Study 12186195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization advice for older infants
Number of subjects: 162
Study 12186195 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antibiotics prescription
Number of subjects: 162
Study 12186195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission after advice
Number of subjects: 162
Study 12186195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission refusal
Number of subjects: 162
Study 12186195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality after hospitalization
Number of subjects: 162
Study 10822908 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 10
Study 10822908 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solutions (HFG, LFG, GLU, BAN, SUG)
Number of subjects: 10
Study 10822908 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate and/or electrolytes in hydration solutions
Number of subjects: 10
Study 8856384 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed skin
Number of subjects: 0
Study 8856384 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated inflamed skin (44 degrees C)
Number of subjects: 0
Study 8856384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff occlusion method (same skin temperature)
Number of subjects: 0
Study 1628294 — intervention group
Group type: COMPARATOR
Intervention: Active control agent
Number of subjects: 6
Study 6230217 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 110
Study 31294619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphencyprone immunotherapy with intralesional meglumine antimoniate (MA)
Number of subjects: 46
Study 31294619 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (MA) alone
Number of subjects: 46
Study 30489151 — intervention group
Group type: EXPERIMENTAL
Intervention: DiLEP
Number of subjects: 157
Study 29722481 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered physical activity intervention (educational materials, activity monitor, interactive website)
Number of subjects: 97
Study 29722481 — intervention group
Group type: COMPARATOR
Intervention: Control group (activity monitor and educational materials)
Number of subjects: 97
Study 29722481 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered physical activity intervention
Number of subjects: 97
Study 29722481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 26460571 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min brief advice (BA) session
Number of subjects: 598
Study 26460571 — intervention group
Group type: EXPERIMENTAL
Intervention: 60- to 90-min brief motivational intervention (BMI)
Number of subjects: 598
Study 26460571 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (AO) control
Number of subjects: 598
Study 25273912 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/hydrochlorothiazide (HCTZ)
Number of subjects: 94
Study 25273912 — intervention group
Group type: COMPARATOR
Intervention: maximum doses of ARB
Number of subjects: 94
Study 22850442 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of rosuvastatin
Number of subjects: 51
Study 22850442 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 51
Study 20440152 — intervention group
Group type: COMPARATOR
Intervention: Quilting sutures only (group 1)
Number of subjects: 26
Study 20440152 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Quixil sealant and marginal quilting sutures (group 2)
Number of subjects: 26
Study 18537963 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam IV (2 mg)
Number of subjects: 8
Study 18537963 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam oral (7.5 mg)
Number of subjects: 8
Study 18537963 — intervention group
Group type: EXPERIMENTAL
Intervention: 1'-hydroxymidazolam IV
Number of subjects: 8
Study 18537963 — intervention group
Group type: EXPERIMENTAL
Intervention: 1'-hydroxymidazolam oral
Number of subjects: 8
Study 18537963 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between midazolam concentrations in plasma and saliva
Number of subjects: 8
Study 15944167 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC + CBT
Number of subjects: 69
Study 15944167 — intervention group
Group type: COMPARATOR
Intervention: SMC
Number of subjects: 69
Study 11906339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (ATCC 53103) for 5.5 months (2.5 months before, 1 month during, and 2 months after the birch-pollen season)
Number of subjects: 36
Study 11906339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10364646 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric magnetic resonance imaging assessment of the hippocampal region
Number of subjects: 50
Study 10364646 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 members)
Number of subjects: 50